STADA Ad hoc and press releases
Archive
2011
12/30/2011Ad hoc Update according §15 WpHG
STADA: Purchase of a branded product portfolio in Eastern Europe as well as in the Middle East successfully concluded – Central Europe still open
12/05/2011
Corporate News
STADA subsidiary increases commitment to charity
12/01/2011
Corporate News
STADA strengthens long-term refinancing with successful securing of promissory notes in the amount of EUR 400 million
11/23/2011
Corporate News
STADA sales companies very successful in large-volume 7th AOK tender in the German generics market
11/10/2011
Corporate News
STADA: Stabilization of business outlook in Serbia after letter of comfort from Serbian government
11/10/2011
Corporate News
STADA 1-9/2011: Good development of sales and operating earnings – High burden on reported key earnings figures through one-time special effects – Confirmation of long-term growth targets
11/09/2011
Ad hoc Update according §15 WpHG
STADA signs contract on the purchase of a generics business in Switzerland
10/31/2011
Corporate News
STADA sales companies very successful in tenders for discount agreements with various German public health insurance organizations
09/21/2011
Ad hoc Release according §15 WpHG
STADA: Increased risk of default on outstanding receivables from Serbian pharmaceutical wholesalers leads to burdening one-time special effects of approx. EUR 97 million before taxes
08/30/2011
Corporate News
STADA and Richter cooperate for development of two biosimilar products for two monoclonal antibodies: Rituximab and Trastuzumab
08/11/2011
Corporate News
STADA: Positive business development in H1/2011 – Increase of Group sales and all key earnings figures – Outlook remains positive for 2011/2012
08/01/2011
Corporate News
STADA sales companies achieve very good results in fourth DAK tender in the German generics market
07/22/2011
Ad hoc Update according §15 WpHG
STADA and Grünenthal sign contracts on the purchase of a branded product portfolio in Central and Eastern Europe as well as the Middle East
06/16/2011
Corporate News
STADA AGM 2011: Executive Board continues to expect further growth in Group sales and earnings in 2011 and 2012
05/26/2011
Corporate News
STADA acquires British branded product Cetraben® for GBP 30 million (approx. EUR 34.6 million)
05/19/2011
Ad hoc Release according §15 WpHG
STADA negotiating the purchase of a generics business in Switzerland
05/12/2011
Ad hoc Release according §15 WpHG
STADA and Grünenthal in exclusive negotiations on the purchase of a branded product portfolio in Central and Eastern Europe as well as the Middle East for approx. EUR 360 million
05/12/2011
Corporate News
STADA: Positive business development in Q1/2011 – Increase of Group sales and all key earnings figures – Outlook remains positive for 2011/2012
05/11/2011
Corporate News
STADA Group achieves strong result in 6th AOK tender in the German generics market
03/30/2011
Corporate News
STADA: Good operating results confirm successful financial year 2010 – positive outlook for 2011/2012
02/28/2011
Ad hoc Release according §15 WpHG
STADA: 2010 preliminary results confirm operationally successful year – dividend to amount to EUR 0.37 with unchanged distribution ratio – positive outlook for 2011/2012
2010
11/11/2010Corporate News
STADA: Group sales increased in 1-9/2010 – adjusted EBITDA went up considerably – high burdening one-time special effects – confirmation of outlook for 2010
09/28/2010
Ad hoc Release according §15 WpHG
STADA: Burdening special effects in the amount of approx. EUR 29.5 million before taxes as a result of liquidity problems of Serbian wholesalers
09/03/2010
Corporate News
STADA: Executive Board structure secured for the long term
08/12/2010
Corporate News
STADA: Good Group development as expected in H1/2010 – Group sales +3% – Net income +4% – EBITDA +15% – Initial successes with implementation of "STADA – build the future" – Outlook remains positive for 2010
07/26/2010
Ad hoc Release according §15 WpHG
STADA: Dr. Axel Müller will be the new Chief Production and Development Officer – Christof Schumann resigns from Executive Board responsibilities
06/08/2010
Corporate News
STADA AGM 2010: Focus on long-term growth targets for 2014
06/07/2010
Ad hoc Release according §15 WpHG
STADA's targets for 2014: EBITDA ca. EUR 430 mio with sales of ca. EUR 2.15 bn – “STADA – build the future” aiming to sustainably increase earnings introduced – total burdening one-time special effects of ca. EUR 50 mio, of which ca. EUR 10 mio in 2010
05/12/2010
Corporate News
STADA: Very good results in Q1/2010 – Group sales +5% – Net income +17% – EBITDA +12% – Outlook remains positive for 2010
05/10/2010
Ad hoc Release according §15 WpHG
STADA: Appointment of Executive Board member Christof Schumann not extended
04/14/2010
Corporate News
STADA: STADA Arzneimittel AG successfully places EUR 350 million bond
03/30/2010
Corporate News
STADA 2009: Good results in a difficult environment – net income significantly improved – positive outlook for 2010
03/01/2010
Ad hoc Release according §15 WpHG
STADA: Net profit significantly improved – dividend set for further increase based on good preliminary results for 2009 – Positive outlook for 2010
2009
11/17/2009Ad hoc Release according §15 WpHG
STADA: Carl Ferdinand Oetker appointed new Member of the Supervisory Board
11/12/2009
Corporate News
STADA: Revived business development as expected in Q3/2009 - development as planned in 1-9/2009 - confirmation of minimum goal for 2009
10/29/2009
Ad hoc Release according §15 WpHG
STADA: Helmut Kraft named Chief Financial Officer
08/24/2009
Ad hoc Release according §15 WpHG
STADA: Changes on the Supervisory Board – Dr. Martin Abend elected new Chairman of the Supervisory Board
08/12/2009
Corporate News
STADA with development as planned in H1/2009: Sales: EUR 755.2 million, net income EUR 48.3 million – outlook confirmed
08/12/2009
Ad hoc Release according §15 WpHG
STADA Chief Financial Officer departs
06/10/2009
Corporate News
STADA: Changes among the employee representatives on the Supervisory Board
06/10/2009
Corporate News
STADA AGM 2009: Executive Board continues to see the chance for growth in terms of sales and net income also in 2009
05/14/2009
Corporate News
STADA Q1/2009 in the upper planning area: Sales EUR 375.9 million; EBITDA EUR 67.5 million; net income EUR 24.1 million
03/26/2009
Corporate News
STADA 2008: Record sales – decrease of earnings with high special effects – open outlook: adjusted EBITDA 2009 at least EUR 250 million
03/02/2009
Ad hoc Release according §15 WpHG
STADA: preliminary results 2008: record sales – decrease of earnings with high special effects – reduced dividend proposal – updated outlook: adjusted EBITDA 2009 at least EUR 250 million
2008
12/19/2008Ad hoc Release according §15 WpHG
STADA: One-time burden on net income 2008 following Olanzapin patent decision
12/05/2008
Corporate News
STADA: Strong result in AOK tenders in the German generics market
11/13/2008
Corporate News
STADA results 1-9/2008: Sales +13%, net income +18% – outlook confirmed
08/13/2008
Corporate News
STADA: satisfactory growth in H1/2008 – subdued growth dynamic
08/12/2008
Ad hoc Release according §15 WpHG
STADA Executive Board smaller
07/28/2008
Ad hoc Release according §15 WpHG
STADA: Satisfactory growth in H1/2008 – outlook: subdued growth dynamic
06/10/2008
Corporate News
STADA AGM: Executive Board gives positive outlook – Supervisory Board confirmed
05/14/2008
Corporate News
STADA:Double-digit growth in Q1/2008: Sales +11%, net income +16%
03/27/2008
Corporate News
STADA 2007: twelfth year of growth in sales and earnings – positive outlook
03/06/2008
Ad hoc Release according §15 WpHG
STADA dividend to rise by 15% after good preliminary results 2007
2007
12/19/2007Corporate News
STADA receives approval for Erythropoietin-zeta – market launch in Q1/2008
11/14/2007
Corporate News
STADA: Strong growth in 1-9/2007: Sales +25%, operating profit +41%
10/19/2007
Corporate News
STADA receives “positive opinion” for Epo-zeta from EMEA
09/28/2007
Ad hoc Release according §15 WpHG
STADA restructures German generics sales – one-time expense approx. EUR 29 mill.
09/28/2007
Corporate News
STADA: Health care reform destroys 230 jobs in German sales
09/21/2007
Ad hoc Release according §15 WpHG
STADA: Acquisition of the British Forum Bioscience successfully completed
09/17/2007
Corporate News
STADA sales companies complete discount contracts with AOK for 23 APIs
08/31/2007
Ad hoc Update according §15 WpHG
STADA: Acquisition of the Russian pharma group MAKIZ successfully completed
08/31/2007
Ad hoc Release according §15 WpHG
STADA acquires UK pharma Group Forum Bioscience for approx. EUR 55.6 million
08/14/2007
Corporate News
STADA: Strong growth continues in H1/2007 – sales +27%, net income +38%
08/03/2007
Ad hoc Release according §15 WpHG
STADA acquires Russian pharma group MAKIZ for approx. EUR 125 million
07/02/2007
Ad hoc Release according §15 WpHG
STADA: Well over 20% sales growth in the German generics business in Q2/2007
06/20/2007
Corporate News
STADA AGM 2007: Executive Board confirms forecast of 12th record year in a row
06/15/2007
Corporate News
STADA's 2004 Annual Shareholders' Meeting: Executive Board sees STADA continuing on growth course in the medium term
05/15/2007
Corporate News
STADA: Successful start in 2007 – Q1: sales +20%, EBIT +28%, net income +22%
03/29/2007
Corporate News
STADA Group results 2006 confirm eleventh record year – optimistic outlook
03/05/2007
Ad hoc Release according §15 WpHG
STADA dividend to rise by 59% after very good preliminary results 2006
2006
11/20/2006Corporate News
STADA reorganizes Biosimilar project – Epo-zeta distribution rights to Hospira
11/20/2006
Ad hoc Release according §15 WpHG
STADA reorganizes Biosimilar project – Epo-zeta distribution rights to Hospira
11/20/2006
Ad hoc Release according §15 WpHG
STADA ordnet Biosimilar-Projekte neu –
Epo-zeta-Vertriebsrechte an Hospira
11/14/2006
Corporate News
STADA: growth after nine months of 2006: Sales +18%, adjusted net income +27%
09/08/2006
Corporate News
After squeeze-out procedure STADA now holds 100% of Hemofarm shares
08/22/2006
Corporate News
STADA: Sale of US business executed as per contract from July 13, 2006
08/22/2006
Corporate News
STADA: Sale of US business executed as per contract from July 13, 2006
08/10/2006
Corporate News
STADA: Strong growth continues in H1/2006 – sales +18%, net income +32%
08/09/2006
Ad hoc Update according §15 WpHG
STADA: takeover offer for Hemofarm successful – acquisition of 97.9% of the shares
08/04/2006
Ad hoc Release according §15 WpHG
STADA: New Executive Board Member for Procurement, Production and Logistics
08/04/2006
Corporate News
STADA: Appointment of the Executive Board extended
07/14/2006
Corporate News
STADA bids for Serbian Hemofarm – access to 59% contractually agreed
07/14/2006
Ad hoc Release according §15 WpHG
STADA bids for Serbian Hemofarm – access to 59% contractually agreed
07/13/2006
Ad hoc Release according §15 WpHG
STADA: Contract for the sale of US subsidiary STADA Inc.
06/30/2006
Corporate News
STADA: Approval documents for Erythropoietin biosimilar submitted to EMEA
06/14/2006
Corporate News
STADA AGM: Executive Board confirms further growth course in sales and earnings
05/30/2006
Corporate News
STADA: Price reductions in the German Market – unchanged Growth Prognosis
05/15/2006
Corporate News
STADA: Very successful Q1/2006 – profit +30% (adjusted +36%), sales +22%
03/30/2006
Corporate News
STADA: Final financial figures for 2005 confirm robust growth course
03/06/2006
Ad hoc Release according §15 WpHG
STADA: Preliminary figures 2005 confirm growth course – optimistic outlook
01/10/2006
Corporate News
STADA: Annual sales over 1 billion Euros for the first time
2005
12/22/2005Corporate News
STADA: Current changes in STADA’s Executive Board
12/12/2005
Ad hoc Release according §15 WpHG
STADA: Product acquisitions (e.g. Mobilat®) strengthen European brand business
11/10/2005
Corporate News
STADA: Strong operative growth in the first nine months of 2005
10/12/2005
Ad hoc Release according §15 WpHG
STADA: Special effects reduce net income in 2005 – positive outlook for 2006
08/11/2005
Corporate News
STADA: Results of the first half of 2005
confirm record course
06/24/2005
Corporate News
STADA: No mandate for the search for a buyer
06/14/2005
Corporate News
STADA AGM 2005: Board Presents Prospect of Further Record Years
05/12/2005
Corporate News
STADA: Successful start to Q1/2005 -
prospects for tenth record year
05/11/2005
Corporate News
STADA acquires majority interest in Chinese pharmaceuticals company BCP
04/11/2005
Ad hoc Release according §15 WpHG
STADA acquires Portuguese Generics supplier Ciclum
03/30/2005
Corporate News
STADA: Record Results in 2004 -
Optimistic Outlook for 2005
03/04/2005
Corporate News
STADA: 9th record year in 2004 - Positive outlook - Dividend rise proposed
02/28/2005
Corporate News
STADA: Peter Niemann, Chief Production and Technology Officer, resigns
01/25/2005
Corporate News
STADA: Nizhpharm acquisition
successfully concluded
2004
12/22/2004Ad hoc Update according §15 WpHG
STADA successfully concludes negotiations to acquire Nizhpharm
11/11/2004
Corporate News
STADA: Sales and earnings increased in Q3/2004 - Prospects improved as expected
11/09/2004
Ad hoc Release according §15 WpHG
STADA launches share buyback
11/08/2004
Ad hoc Release according §15 WpHG
STADA intends to acquire Russian pharmaceutical company Nizhpharm
10/19/2004
Ad hoc Release according §15 WpHG
STADA strengthens Branded Products business with product acquisitions in Italy
08/12/2004
Corporate News
STADA H1 2004: continued sales growth
- weaker earnings mainly due to GMG
08/12/2004
Ad hoc Release according §15 WpHG
STADA H1 2004: continued sales growth
- weaker earnings mainly due to GMG
07/28/2004
Ad hoc Release according §15 WpHG
STADA to carry out de facto 1:1 stock split after close of trading on 07/30/2004
06/15/2004
Corporate News
STADA's 2004 Annual Shareholders' Meeting: Executive Board sees STADA continuing on growth course in the medium term
06/15/2004
Ad hoc Release according §15 WpHG
STADA reduces forecast for 2004
06/09/2004
Corporate News
Minister President Koch visits STADA
05/13/2004
Ad hoc Release according §15 WpHG
STADA started 2004 again with double-digit growth in sales and earnings
04/26/2004
Ad hoc Release according §15 WpHG
STADA: De facto stock split through planned issue of bonus shares
03/30/2004
Ad hoc Release according §15 WpHG
STADA: Record results for 2003; dividend to be increased; optimistic outlook
03/30/2004
Corporate News
STADA: Record results for 2003; dividend to be increased; optimistic outlook
02/26/2004
Ad hoc Release according §15 WpHG
STADA expands oncologics business with a strategic partnership with LipoNova
02/25/2004
Ad hoc Release according §15 WpHG
STADA will be first to launch mirtazapine
as a generic drug on the German market
2003
11/18/2003Ad hoc Release according §15 WpHG
STADA: Nine-Month Records Confirm Optimistic Outlook
11/18/2003
Corporate News
STADA: Nine-Month Records Confirm Optimistic Outlook
10/14/2003
Ad hoc Release according §15 WpHG
STADA Successfully Settles the Placement of 2nd Tranche of Capital Increase
10/14/2003
Corporate News
STADA Successfully Settles the Placement of 2nd Tranche of Capital Increase
10/13/2003
Ad hoc Release according §15 WpHG
STADA Places Second Tranche of
Capital Increase
09/26/2003
Ad hoc Release according §15 WpHG
STADA fixes subscription price for first tranche of capital increase at EUR 37.50
09/26/2003
Corporate News
STADA fixes subscription price for first tranche of capital increase at EUR 37.50
09/22/2003
Ad hoc Release according §15 WpHG
STADA seeks to strengthen its equity base
09/22/2003
Corporate News
STADA seeks to strengthen its equity base
09/03/2003
Ad hoc Release according §15 WpHG
STADA acquires branded products from redinomedica
08/26/2003
Ad hoc Release according §15 WpHG
STADA: Record first half year results - optimistic for further growth
08/26/2003
Corporate News
STADA: Record first half year results - optimistic for further growth
06/24/2003
Corporate News
STADA's 2003 Shareholders' Meeting:
Looking forward to the eighth record year
in a row
05/20/2003
Ad hoc Release according §15 WpHG
STADA: Excellent Start.
Record Result Q1 2003
04/08/2003
Ad hoc Release according §15 WpHG
STADA: Record results in 2002 confirm clear growth course
04/08/2003
Corporate News
STADA: Record results in 2002 confirm clear growth course
03/10/2003
Ad hoc Release according §15 WpHG
STADA strengthens UK generics business through acquisition
02/12/2003
Corporate News
STADA Health Management Endowment Professorship at Europa Fachhochschule Fresenius
01/17/2003
Corporate News
Fidelity reports investment in STADA
01/09/2003
Corporate News
STADA strengthens distribution in Italy by acquiring majority stake in Pharmajani
2002
12/10/2002Corporate News
STADA Executive Board Confirmed and Expanded
11/19/2002
Ad hoc Release according §15 WpHG
STADA: Sales and earnings records
after the first nine months of 2002
11/19/2002
Corporate News
STADA: Sales and earnings records
after the first nine months of 2002
10/02/2002
Corporate News
STADA’s warrants have been a success story
09/30/2002
Corporate News
STADA establishes joint venture in Brazil
08/26/2002
Ad hoc Release according §15 WpHG
STADA: Half-year results confirm raised forecast
07/24/2002
Ad hoc Release according §15 WpHG
STADA implements the Shareholders' Meeting resolution to repurchase shares
07/02/2002
Corporate News
STADA Arzneimittel AG and Rösch AG:
Partnership in Needle-Free Application
of Low-Molecular Heparin
06/25/2002
Corporate News
STADA: Shareholders overwhelmingly
approve growth course
06/25/2002
Ad hoc Release according §15 WpHG
STADA: Sales and earnings
forecast raised for 2002
06/21/2002
Ad hoc Release according §15 WpHG
STADA Acquires Three Vinca-Alkaloid Oncological Products from Lilly
05/17/2002
Corporate News
STADA finalizes acquisition of Crinos
05/14/2002
Ad hoc Release according §15 WpHG
STADA: Q1 earnings surpass expectations
04/22/2002
Ad hoc Release according §15 WpHG
STADA: Record results and optimistic growth forecast
04/22/2002
Corporate News
STADA: Record results and optimistic growth forecast
04/17/2002
Ad hoc Release according §15 WpHG
STADA acquires Bayvit, Spain’s second-largest generic-drug company
04/08/2002
Corporate News
STADA’s CEO H. Retzlaff extends contract to 2008
03/19/2002
Ad hoc Release according §15 WpHG
STADA signs letter of intent regarding the acquisition of the Marketing and Sales Operations of the Italian pharmaceutical company Crinos
03/12/2002
Corporate News
STADA confirms Biogenerics forecasts
03/11/2002
Corporate News
STADA increases share in Spain‘s Ciclum Farma
01/08/2002
Ad hoc Release according §15 WpHG
STADA is on track to expand U.S. business
2001
12/10/2001Ad hoc Release according §15 WpHG
STADA: "Sales billionaire"
12/04/2001
Ad hoc Release according §15 WpHG
STADA to increase dividend by +20%
11/16/2001
Corporate News
STADA: Strong increase in earnings
11/16/2001
Ad hoc Release according §15 WpHG
STADA: Strong increase in earnings
11/07/2001
Ad hoc Release according §15 WpHG
STADA acquires US generics business
10/29/2001
Ad hoc Release according §15 WpHG
STADA now with one stock category
08/22/2001
Corporate News
STADA Arzneimittel AG in the first six months of 2001: Successful course continues
08/22/2001
Ad hoc Release according §15 WpHG
STADA Arzneimittel AG in the first six months of 2001: Successful course continues
07/23/2001
Corporate News
STADA now with MDAX listing
07/23/2001
Corporate News
STADA receives a declaration of discontinuance from DocMorris with regard to the unlawful sales of STADA products
07/02/2001
Ad hoc Release according §15 WpHG
STADA acquires brand product Plastulen® N with DM 5.6 million in annual sales
06/27/2001
Ad hoc Release according §15 WpHG
STADA has achieved MDAX listing
06/19/2001
Corporate News
STADA Shareholders’ Meeting 2001: single class of stock increases chances for MDAX inclusion
06/19/2001
Corporate News
STADA: On track for successful growth
06/07/2001
Corporate News
STADA: Best German-Language Pharmaceutical Web Site Now Even Better
05/11/2001
Corporate News
STADA:
Significant earnings growth in Q1 2001
05/11/2001
Ad hoc Release according §15 WpHG
STADA: Q1 EBITDA increased by 25%
and Q1 net income by 23%
04/24/2001
Corporate News
STADA Arzneimittel AG - Fiscal year 2000
04/24/2001
Ad hoc Release according §15 WpHG
STADA: Record results and growth forecast - Conversion of preferred stock to common stock planned
03/20/2001
Ad hoc Release according §15 WpHG
STADA raises sales in 2000 by +32% to DM 913.7 million
03/07/2001
Ad hoc Release according §15 WpHG
STADA continues Asian expansion with two acquisitions
02/07/2001
Corporate News
Dr. Eckhard Brüggemann elected as
the new Chairman of the Supervisory Board
01/24/2001
Corporate News
STADA expects to boost expansion with biogenerics after having signed new agreements
01/24/2001
Ad hoc Release according §15 WpHG
STADA expects to boost expansion with biogenerics after having signed new agreements
2000
11/24/2000Corporate News
STADA website ranked first in an independent study of all German-language pharmaceuticals internet sites
11/16/2000
Corporate News
STADA reports high growth in sales
and earnings for Q3/2000
10/26/2000
Corporate News
STADA acquires OTC products in Italy
09/26/2000
Corporate News
STADA Arzneimittel AG
is to execute a share split
08/28/2000
Corporate News
STADA - successful and independent
08/23/2000
Corporate News
Sales and earnings growth at STADA is stronger than expected
08/23/2000
Ad hoc Release according §15 WpHG
STADA Arzneimittel AG exceeds sales
and earnings targets in the 1st half of 2000
07/03/2000
Corporate News
STADA is the first generics company to add new dosage forms and new active strengths to its Omeprazol product range
06/20/2000
Corporate News
STADA continues its growth course - results of the General Meeting on June 19, 2000
06/19/2000
Ad hoc Release according §15 WpHG
STADA increases sales targets for 2000 -
Consolidated sales set to rise by over 25%
06/02/2000
Ad hoc Release according §15 WpHG
STADA invests in Biogenerics-Project
05/10/2000
Corporate News
STADA Arzneimittel AG
Quarterly Sales Up 36 Percent
04/27/2000
Ad hoc Release according §15 WpHG
STADA Arzneimittel AG Reports Excellent Fiscal Year for 1999 Sales up 37.5 percent to DM 692 million - 2000 off to a brilliant start - stock split announced to stimulate market price
04/27/2000
Corporate News
STADA Arzneimittel AG - The Health Company Presents Brilliant Results
Sales up 37.5 percent to DM 692 million in 1999 - 2000 off to a brilliant start - stock split announced to stimulate market price
03/08/2000
Ad hoc Release according §15 WpHG
At today's extraordinary shareholders' meeting, STADA will present its excellent preliminary results for 1999 and announce capital measures designed to consolidate the Group's financial foundations for further dynamic growth
02/11/2000
Corporate News
STADA to be included in S-DAX starting March 20, 2000
01/28/2000
Corporate News
STADA well on its way to be included in S-DAX
01/26/2000
Corporate News
Extraordinary shareholders' meeting of
STADA Arzneimittel AG on 08.03.2000 -
STADA is applying for a listing on the SMAX index
01/26/2000
Ad hoc Release according §15 WpHG
STADA and Dowelhurst set up sales joint venture for generics in Great Britain
1999
11/18/1999Ad hoc Release according §15 WpHG
Following record results in the 3rd quarter of 1999, STADA confirms plans for a further dividend increase
09/22/1999
Corporate News
STADA acquires distribution rights for Multilind® healing ointment from Bristol-Myers Squibb / Distribution in Germany by NIDDApharm
09/08/1999
Corporate News
STADA wins Omeprazol dispute with Astra
08/25/1999
Ad hoc Release according §15 WpHG
STADA once again achieves record sales and profits in the first half of 1999 - Management Board holds out possibility of further dividend increase
06/29/1999
Ad hoc Release according §15 WpHG
STADA Arzneimittel AG again increases the forecast for 1999 -Sales growth in excess of 20%. New record turnover of DM 620-630 million possible
06/29/1999
Corporate News
STADA subsidiary NIDDApharm enters the German vaccine market
05/25/1999
Corporate News
STADA donates medical aid to Kosovo
worth DM 800,000.00
04/28/1999
Ad hoc Release according §15 WpHG
STADA Arzneimittel AG - 1998 best financial year for the third time in succession. Sales increased in the first quarter of 1999 by 45%. Board of Management expanded from 1 May 1999.
04/28/1999
Corporate News
STADA Arzneimittel AG - 1998 best financial year for the third time in succession. Sales increased in the first quarter of 1999 by 45%. Board of Management expanded from 1 May 1999.
